PROGRESS TOWARDS AN HIV VACCINE

We have made tremendous progress in the treatment and prevention of HIV.

...but HIV remains one of the greatest global health challenges of our time.

HIV affects 37 million people around the world.

1.8 million new cases every year.

J&J and its partners are evaluating novel vaccine concepts for HIV.

Together our hope is to make HIV history.

“Developing a vaccine against HIV is a top priority and our best hope for a world without AIDS. Finding an effective HIV vaccine to protect people at risk has been a major scientific challenge, but today there is new optimism that we can get there.”

Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson

Reference
We are innovating to help patients currently facing a lifetime of treatment. We are investigating strategies to achieve remission. And our ultimate goal is to find a preventive vaccine for HIV, because experts agree that this is needed to turn the tide of the HIV pandemic.

Johnson & Johnson is bringing together:

- AdVac®/PER.C6® technology
- Expert teams
- Global research and funding partners
- Manufacturing capabilities

Mosaic vaccines are delivered through viral vectors based on our unique AdVac® and PER.C6® technology. PER.C6 is also the manufacturing platform for the HIV envelope proteins used in the boost vaccinations.

Viral vectors are combined with soluble proteins to form mosaic-based heterologous prime-boost vaccine regimens which first prime and then boost the immune system.

With our partners, we have initiated the first efficacy study for a mosaic-based investigational HIV-1 preventive vaccine. The study will evaluate whether a lead vaccine regimen comprising the 4-component Ad26 mosaic candidate and a Clade C gp140 soluble protein is able to reduce the incidence of HIV infection among women in sub-Saharan Africa.